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Abstract
Background and objectives: Painful phenomenon is one of the most important and complex
experiences. Phentolamine is a non-selective alpha-adrenergic antagonist. The objective of
this study was to compare the effect of increasing doses of phentolamine into subarachnoid
space in rats in the modulation of painful phenomenon.
Methods: 84 male Wistar rats were divided into formalin and plantar incision groups, subdivided
into six subgroups (n = 7). Control group received only saline (10L); active subgroups received
phentolamine 10mg (GF10), 20mg (GF20), 30mg (GF30), 40mg (GF40), and 50 g (GF50). In
formalin group, pain was induced by injection of 50L of 2% formalin in dorsal region of right
posterior paw. In plantar incision group, pain was induced by plantar incision and evaluated using
von Frey ﬁlaments. Induction and maintenance of anesthesia were performed with 3% halothane
for catheter placement into subarachnoid space and plantar incision. Statistical analysis was
performed using the JMP program from SAS with 5% signiﬁcance level.
Results: Phentolamine at doses of 20 and 30 g increased the algesic response in the intermediate
phase of the formalin test. In plantar incision test, it had hyperalgic effect on ﬁrst, third, ﬁfth,
and seventh days at a dose of 10 g and on ﬁrst, third, and ﬁfth days at a dose of 20 g and on
ﬁfth day at a dose of 30 g. Study conducted at Faculdade de Medicina do ABC, Santo André, SP, Brazil.
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Conclusion: Subarachnoid administration of phentolamine showed hyperalgesic effect, possibly
due to the involvement of different subclasses of alpha-adrenergic receptors in modulating pain
pathways.
© 2014 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights
reserved.
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Efeito hiperálgico da fentolamina, por via subaracnoidea, em ratos
Resumo
Justiﬁcativa e objetivos: O fenômeno doloroso é uma das mais importantes e complexas exper-
iências. A fentolamina é antagonista alfa-adrenérgico não seletivo. O objetivo foi comparar os
efeitos de doses crescentes da fentolamina, por via subaracnóidea, em ratos na modulac¸ão do
fenômeno doloroso.
Método: Foram usados 84 ratos Wistar machos, divididos nos grupos formalina e incisão plantar,
subdivididos em seis subgrupos (n = 7). No subgrupo controle (GC) apenas salina (10L), nos
subgrupos ativos, 10g de fentolamina (GF10), 20g (GF20), 30g (GF30), 40g (GF40) e
50g (GF50). No grupo formalina, a dor foi induzida com injec¸ão de 50L de formalina a 2%,
na região dorsal da pata posterior direita. No grupo incisão plantar, a dor foi induzida por
incisão plantar e avaliac¸ão pelos ﬁlamentos de von Frey. Induc¸ão e manutenc¸ão anestésica com
halotano a 3% para introduc¸ão de cateter no espac¸o subaracnóideo e feitura da incisão plantar.
Análise estatística dos resultados pelo programa JMP do SAS com nível de signiﬁcância 5%.
Resultados: A fentolamina nas doses de 20 e 30g produziu aumento da resposta álgica na fase
intermediária do teste da formalina. No teste da incisão plantar, promoveu efeito hiperálgico
no primeiro, terceiro, quinto e sétimo dias na dose de 10g, no primeiro, terceiro e quinto dias
na dose de 20g e no quinto dia na dose de 30g.
Conclusão: A fentolamina por via subaracnóidea promoveu efeito hiperálgico, possivelmente
pela participac¸ão de diferentes subclasses de receptores alfa-adrenérgicos nas vias modu-
latórias da dor.
© 2014 Sociedade Brasileira de Anestesiologia. Publicado por Elsevier Editora Ltda. Todos os
direitos reservados.
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dioxide. The rats were anesthetized with 3% halothane inntroduction
he passage of information through the posterior horn of
he spinal cord (PHSC) toward the rostral levels of the cen-
ral nervous system (CNS) undergoes profound excitatory
nd inhibitory inﬂuences. The pharmacology elucidation of
hese modulatory systems has guided the ability assessment
f speciﬁc receptors.1
Neurotransmitters, amino acids, and neuropeptides are
eleased by primary afferent terminals into PHSC, where
hey act in nociceptive transmission modulation. Among
thers, the excitatory amino acids (glutamate and aspar-
ate); neurotransmitters and neuropeptides, including the
achykinins (substance P [SP], neurokinin A [NKA], and neu-
okinin B [NKB]); calcitonin related gene peptide (CGRP);
holecystokinin (CCK); somatostatin; nitric oxide (NO);
rostaglandin (PG); galanin; enkephalins; and endorphins
re highlighted.2
Phentolamine, an alpha-adrenergic competitive antago-
ist, which belongs to the non-selective imidazoline group
nd has similar efﬁcacy on alpha 1 (1) and alpha 2 (2) can
lso block 5-HT receptors and potassium channels (K+) and
ause the release of histamine by mast cells.3
1
t
pThis study evaluated the effects of escalating doses of
hentolamine, administered in the subarachnoid space, on
ain-induced in rats using the modiﬁed formalin test and
he incision plantar test to verify if the involvement of
drenergic pathways in descending pain inhibitory system
s phentolamine dose-dependent.
ethod
xperimental procedures followed the Ethical Standards
f the International Association for the Study of Pain
IASP), which regulates animal experiments (Committee for
esearch and Ethical Issues of the IASP, 1983), and the
roject was approved by the Comitê de Ética no Uso de
nimais Ceua/Unitau, protocol # 019/11. In total, we used
4 male Wistar rats, weighing 220--300 g, which were indi-
idually placed in transparent glass chamber measuring
5 cm× 25 cm× 15 cm, with a hole in front and back to allow
ntrance and exit of oxygen, anesthetic gases, and carbon00% oxygen. When the rats showed inability to get around
he chamber, he was removed and placed in the supine
osition with the abdomen over a plastic cylinder, with his
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Figure 1 Mean number of animal ﬂinches during the Interme-
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Subarachnoid phentolamine at a dose of 10g provided
hyperalgic effect on plantar incision-induced pain in the
ﬁrst, third, ﬁfth, and seventh days; at a dose of 20g, it
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muzzle in a mask through which he continued to receive the
same halothane concentration.
Subsequently, a polyethylene catheter (PE 10) was cau-
dally introduced into the subarachnoid space, by puncture
with a 22G Tuohy needle, at the midline of the interver-
tebral space above the penultimate lumbar vertebra to
the subarachnoid space, which was identiﬁed by the reﬂex
movement of the tail or one of the hind paws. The catheter
was ﬁxed in the subcutaneous tissue, the skin sutured with
needled nylon 4-0, and at the end of the experiment, after
the animal sacriﬁce with sodium thiopental, lumbar spine
was sectioned to conﬁrm the catheter presence in subarach-
noid space.4
The animals were randomly allocated into two groups:
formalin and plantar incision. Rats in formalin group were
allocated into six subgroups (n = 7 each); the control group
(CG) received 10L subarachnoid saline immediately after
catheter placement; active groups PG10, PG20, PG30, PG40,
and PG50 received via the same route 10L of phentolamine
solution with the respective doses 10g, 20g, 30g, 40g,
and 50g, which, respectively, corresponded to 31.5 nmol,
63 nmol, 94 nmol, 126 nmol and 157 nmol of phentolamine in
sterile saline.
The formalin induced pain (formalin test modiﬁed) was
carried out by administering 50L 2% formalin solution into
the dorsal region of the right hind paw, 25min after saline
or phentolamine administration.5
All paw withdrawals, which were not related to gait,
were recorded regardless of the time that it remained sus-
pended. Counting was done continuously for 60min. The
partial number of withdrawals was recorded every 5min.
The test was divided into three phases: I, Intermediate,
and II. Phase I included the number of ﬂinches during the
ﬁrst 5min, the Intermediate Phase from the 6th to the 20th
minute, and Phase II from the 21st to the 60th minute.
Rats in plantar incision group were allocated into six sub-
groups of seven animals each. Control group (CG) received
10L subarachnoid saline immediately after catheter place-
ment; active groups PG10, PG20, PG30, PG40, and PG50
received via the same route 10L of phentolamine solu-
tion with the respective doses 10g, 20g, 30g, 40g,
and 50g, which, respectively, corresponded to 31.5 nmol,
63 nmol, 94 nmol, 126 nmol and 157 nmol of phentolamine in
sterile saline.
Surgical, longitudinal incision of 1 cm extension wasmade
in the posterior limb of the anesthetized animal, with a
scalpel blade number 11. Skin and fascia of the plantar
region were incised, starting 0.5 cm from the calcaneus
edge and extending toward the toes. The plantaris mus-
cle was elevated and incised longitudinally and the incision
remained intact. After hemostasis with slight pressure on
the surgical site, all plans were approximated and sutured
with two separate points with needled mononylon 4-0.
Hyperalgesia assessment was done by applying von Frey’s
ﬁlaments in the 2nd hour and the 1st, 3rd, 5th, 7th, 14th,
and 21st day after saline or phentolamine administration.6
The solution volume (10L) injected into the subarach-
noid space was deﬁned from previous studies.4,7,8For statistical analysis, we used the JMP® Statistical soft-
ware by SAS Institute (Statistical Analysis System) and the
analysis of variance followed by Dunnett’s test, considering
a signiﬁcance level lower than 5% (p < 0.05).
F
tiate phase of the formalin test in study groups. *Statistically
igniﬁcant difference (p < 0.05).
esults
ain intensity assessed by modiﬁed formalin test
hentolamine, administered in the subarachnoid space
t doses of 20g and 30g produced increased algesic
esponse in the intermediate phase of the modiﬁed formalin
est, as the average number of ﬂinches during the forma-
in test Intermediate Phase ranged from 16.28 in PG10 to
7.95 in PG30. The highest values were found in PG20 and
G30 groups, which showed statistically signiﬁcant differ-
nces compared with the control group (Figs. 1 and 2).
The mean number of ﬂinches during the formalin test
hase I and Phase II showed no statistically signiﬁcant dif-
erences between groups.
ain intensity measured by von Frey’s ﬁlaments, in
urgical incision plantar testTime (min)
igure 2 Mean number of animal ﬂinches during all phases of
he formalin test in study groups.
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Figure 3 Response to von Frey’s ﬁlaments at the 2nd hour
after subarachnoid phentolamine.
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Figure 5 Response to von Frey’s ﬁlaments on the third day
after subarachnoid phentolamine. *Statistically signiﬁcant dif-
ference (p < 0.05).
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Figure 6 Response to von Frey’s ﬁlaments on the ﬁfth day
after subarachnoid phentolamine. *Statistically signiﬁcant dif-
ference (p < 0.05).
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fter subarachnoid phentolamine. * Statistically signiﬁcant dif-
erence (p < 0.05).
rovided hyperalgic effect on the ﬁrst, third and ﬁfth days
f plantar incision-induced pain; and at a dose of 30g,
t provided hyperalgic effect on the ﬁfth day of plantar
ncision-induced pain.
At the 2nd hour and the ﬁrst, third, and ﬁfth days after
ubarachnoid phentolamine application there was less sen-
itivity to von Frey’s ﬁlaments in PG10 and PG20, with
tatistically signiﬁcant differences when compared to CG
Figs. 3--6).
On the seventh day of assessment, increased sensitivity
o von Frey’s ﬁlaments was seen in PG10, with a statistically
igniﬁcant difference compared to CG (Fig. 7).
Assessment in the 14th and 21st days showed no statisti-
ally signiﬁcant differences between groups in sensitivity to
on Frey’s ﬁlaments.iscussion
he descending pain inhibitory system mainly consists of
our interconnected parts of the CNS: (a) cortical and
Figure 7 Response to von Frey’s ﬁlaments on the seventh
day after subarachnoid phentolamine. *Statistically signiﬁcant
difference (p < 0.05).
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diencephalic systems; (b) periaqueductal gray (PAG) and
periventricular matter rich in enkephalins and opioid recep-
tors; (c) rostroventral portion of the bulb, especially the
nucleus raphe magnus (NRM) and (d) adjacent nuclei that
receive excitatory impulses from PAG and, in turn, send
noradrenergic and serotonergic ﬁbers, via the dorsolateral
funiculus, which project to the dorsal horn of the spinal
cord and bulb. The ﬁbers of the descending inhibitory
system mainly terminate in laminae I, II, and V where
they inhibit nociceptive neurons, including interneurons
and ascending tracts that project rostrally, among them
the spinothalamic, spinoreticular, and spinomesencephalic
tracts. Another important ﬁber group that has been included
in the endogenous pain control system formation is locus
coeruleus noradrenergic neurons and central cholinergic
system.2,9--11
To assess the effects of phentolamine on pain pathways,
multiple doses are administered into subarachnoid space in
rats. In this study, we used escalating doses, from previ-
ously reported doses usually administered by other authors
who have shown conﬂicting results and highlighted the need
for studies with varying doses, which motivated this dose-
escalation study.4,8,12
Modiﬁed formalin test is widely used as animal model of
nociception because it produces responses similar to those
occurring in humans. The number of ﬂinches as a device
for quantifying pain behavior induced by formalin is closely
related with the classical formalin test and cardiovascular
changes in response to pain caused by formalin in the paw,
showing close correlation with pain behavior in conscious
animals.13--16
During Phases I and II of the modiﬁed formalin test, there
was no difference between groups, suggesting no interfer-
ence from the noradrenergic system. However, during the
Intermediate Phase, proposed as related to central pain
inhibition, we found a signiﬁcant increase in the number
of ﬂinches, compared with control group, when doses of
20 and 30g were administered via subarachnoid, without
statistically signiﬁcant difference compared with the other
groups.
Studies reporting analgesic effect in the presence of
spinal alpha-2 receptor stimulation suggest that 10g were
insufﬁcient to have agonist effects on these receptors and
that doses higher than 30g may also have agonist effects
on alpha-1 receptors, an effect that antagonizes the effects
of alpha-2 receptor stimulation.17
The mouse model of plantar incision pain proposed by
Brennan et al.6 is very useful for understanding the patho-
physiological mechanisms of pain. In clinical practice, it is
very similar to the pain experienced by patients in postop-
erative period, involuntary and less intense at rest.
Subarachnoid administration of phentolamine in rats at
doses of 10 and 20g showed analgesic characteristics
during the second hour after administration. This can be
explained by the predominance of the central modulatory
effect on low doses of the drug. These low doses are
unable to antagonize the effect of descending noradren-
ergic release, as with the increased dose, this antagonism
prevailed, showing no reduction in sensitivity (analgesia).
However, the dose of 10g administered via subarachnoid
presented hyperalgic effect on the ﬁrst, third, ﬁfth, and sev-
enth days, as well as the dose of 20g on the ﬁrst, third, and
1
1115
fth days. The dose of 30g provided hyperalgesic effect
nly on the ﬁfth day after administration, which suggests
hat in this period without modulatory action, the blockade
f adrenergic receptors with greater selectivity, possibly on
lpha-2 receptors, promoted greater sensitivity and hyper-
lgesia.
Other studies have reported analgesic effect with alpha-
receptor stimulation, located in the spinal cord, by
euronal discharge inhibition 17,18. This could explain the
esults of this experiment, as higher doses of phentolamine
alpha-adrenergic antagonist) could also stimulate alpha-1
eceptor, produce antagonist effect to the effects of alpha-
receptor stimulation, and potentiate the adrenergic effect
n alpha-1 receptors.
The hypothesis that larger doses of the antagonist phen-
olamine could stimulate the alpha-1 adrenergic receptors
nd produce an antagonist effect to the effect of alpha-2
drenergic receptors stimulation and therefore enhance the
drenergic effect on alpha-1 adrenergic receptors should
e elucidated in further studies comparing blockers with
reater selectivity for alpha-1 adrenergic receptors with
igh doses of phentolamine.
onclusion
ifferent doses of subarachnoid phentolamine provide
ifferent effects on pain sensitivity, possibly by the partici-
ation of different subclasses of alpha-adrenergic receptors
n modulating pain pathways.
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